How Pharma Can Avoid the Next Wave of AI Failures
The pharmaceutical industry is entering a moment where the speed of AI is outpacing the systems meant to govern it. Large language models (LLMs) are being woven into regulatory submissions, medical writing, safety surveillance, competitive intelligence, and clinical development. These tools are powerful enough to transform how data is interpreted but also amplify mistakes at unprecedented scale.
What early adopters are learning is not that AI is flawed, but that our field has underestimated how deeply regulatory nuance, data interdependence, and competitive context must be embedded into AI design. The failures we’ve seen are not failures of technology. They are failures of architecture, governance, and assumptions about how these systems reason.
A Growing Imbalance Between Speed and Oversight
Basil Systems' vantage point comes from working alongside regulatory, clinical, and safety teams who are seeking ways to integrate LLMs into their daily workflows. Many of these teams are not resistant to innovation; in fact, they are impatient for it. They face growing submission volumes, increasingly complex regulatory expectations, and competitive landscapes where every month matters – all while under greater budget scrutiny. But in that urgency, shortcuts emerge.
One Fortune 500 company learned this when an off-the-shelf LLM hallucinated FDA approval pathways and cited non-existent guidances, delaying a key program by six months. Another large biopharma built multiple AI tools for different departments, each accurate in isolation but contradictory when compared, leading to more than $2 million in reconciliation work and FDA questions about data consistency. And one global audit revealed that 40 percent of AI-generated safety assessments were unverifiable because the system provided no citations at all.
These were predictable failures, and they now offer critical lessons for every pharma executive.
The Five Most Common LLM Mistakes in Pharma
Below are examples and themes emerging consistently across real-world implementations:
1. Deploying General-Purpose AI for Specialized Regulatory Work
One global organization used an off-the-shelf LLM for regulatory precedent analysis, a tool never designed for high-stakes interpretation. The model hallucinated FDA pathways, invented non-existent guidance documents, and gave summaries that sounded persuasive but were wrong. When the company switched to a reference-based architecture grounded in FDA, EMA, and PMDA documents, hallucinations dropped 64 percent. Fluency without grounding is not a feature; it is a liability.
2. Creating Data Silos Instead of Connected Intelligence
Another large biopharma deployed separate LLMs for clinical, safety, and regulatory teams. Individually, they performed well; collectively, they produced conflicting outputs. Regulators flagged inconsistencies, and internal teams spent more than $2 million reconciling differences. When the company rebuilt its architecture around drug labels – which connects safety, efficacy, and regulatory interpretation – cross-functional review cycles dropped by 70 percent with organizational consistency.
3. Missing Competitive Intelligence Opportunities
A mid-size biotech used an LLM solely for internal document management, giving the model no insight into competitor labels, safety events, pipeline activity, or regulatory actions. As a result, the company overlooked significant white-space opportunities. When external signals were integrated, the system surfaced three uncontested indication opportunities they had previously missed – one of which is now being actively pursued.
4. Lacking Audit Trails and Source Attribution
One global company deployed an AI assistant that delivered fast, confident answers but with no citations. During an audit, 40 percent of AI-generated safety assessments were ruled unverifiable. After regulators raised concerns about data provenance, the team rebuilt the system to require granular attribution (document, section, and version). The result was full traceability and zero regulatory queries on provenance in subsequent submissions.
5. Underestimating Domain Complexity
Perhaps the most common failure occurs when teams believe that a strong, general-purpose LLM can be retrofitted to understand regulatory nuance. One company’s AI vendor treated draft and final guidances as equivalent, missed critical safety signal updates, and misinterpreted precedent hierarchies. When a new system was introduced that was built with explicit regulatory logic and domain expertise, regulatory intelligence dissemination dropped from four weeks to one. Domain intelligence is not an optional enhancement; it is fundamental to the architecture.
What Pharma Leadership Must Do Differently
These examples point to a broader truth: AI is not plug-and-play. It is infrastructure. And when deployed without grounding or context, it accelerates the wrong behaviors as quickly as the right ones. The companies that stumbled did so because they built systems too quickly, on assumptions that didn’t match regulatory reality, with architectures that treated internal data silos with a generalist approach rather than an industry-trained intelligence.
Executives must treat AI outputs the way regulators treat evidence: nothing should be trusted without a clear, traceable source. A model’s confidence is not a justification for belief. AI systems cannot be purpose-built for isolated teams; they must share an authoritative backbone, the drug label, which naturally connects clinical, safety, and regulatory reality. And through it all, human oversight must remain "in the loop."
LLMs must ingest the competitive landscape, not just internal documents. Companies that build internal-only intelligence systems will miss strategic openings and replicate external mistakes. Domain expertise must be built into the system from the beginning. Regulatory nuance, evidence hierarchies, label negotiation dynamics, and safety signal interpretation must shape the architecture.
The Path Forward: Learning From Early Failures
The future of AI in pharma will be defined by who adopts it wisely. The organizations that internalize the lessons of early failures will not only avoid risk – they will operate with clarity and speed their competitors lack. They will spot regulatory patterns earlier, detect competitive openings faster, eliminate contradictory outputs before they reach regulators, and accelerate approvals.
Leaders are recognizing that innovation alone is not enough. Architecture, governance, and domain expertise must evolve alongside it. Pharma doesn’t just need AI. It needs AI that understands the stakes and can verify the insights it derives before delivering them. And it is up to today’s executives to build the systems that make that possible.